AJP - GI Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 263: G802-G809, 1992;
0193-1857/92 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciccotosto, G. D.
Right arrow Articles by Shulkes, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciccotosto, G. D.
Right arrow Articles by Shulkes, A.

AJP - Gastrointestinal and Liver Physiology, Vol 263, Issue 5 802-G809, Copyright © 1992 by American Physiological Society


ARTICLES

Pharmacokinetics and organ specific metabolism of glycine-extended and amidated gastrin in sheep

G. D. Ciccotosto and A. Shulkes
Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia.

Glycine (Gly)-extended gastrin has been described as the inactive precursor form of the biologically active amidated gastrin. The ratio of Gly-extended to amidated gastrin is higher in the circulation than in tissue, suggesting either differential secretion and/or metabolism. Although the distribution of the precursor form is similar in tissue and circulation to its amidated product, the significance of measurable levels of precursor peptide in the circulation is unknown. In this study, we have examined the pharmacokinetic properties and organ-specific metabolism of both the Gly-extended and the amidated forms of gastrin-17 (G-17-Gly and G-17-amide) in the conscious sheep. The metabolic clearance rate, half disappearance time, and production rates were similar for both G-17-Gly and G-17-amide. G-17-Gly was extracted across the head, kidney, and lung but not across the gut and liver. Similarly, G-17-amide was extracted across the head, gut, lung, and kidney but not across the liver. G-17-Gly had no biological activity as evidenced by its failure to stimulate somatostatin secretion nor was there any measurable conversion to amidated gastrin in the circulation. We conclude that the presence of G-17-Gly in the circulation is not the result of a slower clearance and that circulating G-17-Gly is not a precursor for circulating gastrin-amide. The results of this study provide important baseline data for understanding the dynamics of the precursor product relationship between G-Gly and G-amide.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. C. Paterson, G. S. Baldwin, and A. Shulkes
Metabolism of recombinant progastrin in sheep
Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E449 - E456.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. P. Hansen, J. P. Goetze, F. Stadil, and J. F. Rehfeld
The metabolism of gastrin-52 and gastrin-6 in pigs
Am J Physiol Gastrointest Liver Physiol, September 1, 2000; 279(3): G552 - G560.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online